Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Scisparc Ltd (SPRC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/22/2025: SPRC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -81.01% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.46M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.94 | 52 Weeks Range 0.20 - 1.16 | Updated Date 06/29/2025 |
52 Weeks Range 0.20 - 1.16 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.08 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -797.21% |
Management Effectiveness
Return on Assets (TTM) -42.05% | Return on Equity (TTM) -80.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1446531 | Price to Sales(TTM) 2.65 |
Enterprise Value 1446531 | Price to Sales(TTM) 2.65 | ||
Enterprise Value to Revenue 1.11 | Enterprise Value to EBITDA 1.21 | Shares Outstanding 11225800 | Shares Floating 10806161 |
Shares Outstanding 11225800 | Shares Floating 10806161 | ||
Percent Insiders - | Percent Institutions 1.1 |
Upturn AI SWOT
Scisparc Ltd
Company Overview
History and Background
SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company focused on the development of therapies to treat disorders of the central nervous system. Founded as Therapix Biosciences in 2004, it later rebranded as SciSparc Ltd.
Core Business Areas
- Central Nervous System (CNS) Disorders: Develops and commercializes pharmaceutical products and technologies based on cannabinoid science, primarily focusing on Tourette Syndrome, Alzheimer's Disease, Autism Spectrum Disorder, and other neurological conditions.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives. The organizational structure is typical for a clinical-stage biopharmaceutical company.
Top Products and Market Share
Key Offerings
- SCI-110: SCI-110 is SciSparc's lead drug candidate for the treatment of Tourette Syndrome. Market share data specifically for SciSparc's SCI-110 is not readily available, as it is still in clinical development. Competitors include Teva Pharmaceutical Industries (TEVA) with generic medications for Tourette's, and other pharmaceutical companies developing novel therapies.
- SCI-160: SCI-160 is being developed for the treatment of pain. This is a competitive market with many players. Market share is not yet applicable because the drug is in development. Competitors include large pharmaceutical companies with pain medications like Pfizer (PFE), Johnson & Johnson (JNJ).
- CannAmide: A proprietary endocannabinoid-based treatment. Market share is not yet applicable because the drug is in development. Competitors include GW Pharmaceuticals (acquired by Jazz Pharmaceuticals), which developed Epidiolex.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investments in research and development. Cannabinoid-based therapies are an emerging area of interest.
Positioning
SciSparc Ltd. is positioned as a clinical-stage company developing novel cannabinoid-based therapies for CNS disorders. They are smaller than their larger competitors.
Total Addressable Market (TAM)
The total addressable market for CNS disorders is estimated in the hundreds of billions of dollars globally. SciSparc is targeting specific niche markets within the broader CNS space.
Upturn SWOT Analysis
Strengths
- Focus on cannabinoid-based therapies
- Proprietary technologies and formulations
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Smaller market presence compared to competitors
Opportunities
- Growing acceptance of cannabinoid-based therapies
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GWPH (Acquired by Jazz Pharmaceuticals)
- TEVA
- PFE
- JNJ
Competitive Landscape
SciSparc competes with larger pharmaceutical companies. SciSparc aims to differentiate through their focus on cannabinoid science and specific CNS indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its clinical-stage status.
Future Projections: Future growth depends on the success of its clinical trials and ability to secure partnerships. Analyst projections vary.
Recent Initiatives: Recent initiatives include advancing clinical trials and exploring strategic collaborations.
Summary
SciSparc Ltd. is a clinical-stage biopharmaceutical company focused on cannabinoid-based therapies for CNS disorders. Its success depends on the outcomes of its clinical trials, which makes it a high-risk, high-reward investment. They face competition from much larger pharmaceutical players. Partnering with larger firms would increase their likelihood of success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investing in stock market carries risk. Conduct your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scisparc Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-08-30 | CEO & CFO Mr. Oz Adler C.P.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://scisparc.com |
Full time employees 2 | Website https://scisparc.com | ||
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.